In this grow­ing and rapidly evolv­ing cat­e­gory, there are mul­ti­ple oppor­tu­ni­ties for devel­op­ers to part­ner with large-scale orga­ni­za­tions look­ing for ways to improve health, per­for­mance and busi­ness out­comes. Dur­ing this ses­sion we will dis­cuss sig­nif­i­cant neurotech-related ini­tia­tives tak­ing place at large IT, pharma and auto­mo­tive firms, as well as universities. - Chair: Richard Varn, Dis­tin­guished Pres­i­den­tial Appointee at Edu­ca­tional Test­ing Ser­vice (ETS) - Tommy Sagroun, CEO of CogniFit - Peter Freer, Inven­tor and CEO of Freer Logic - Glenn Mor­ri­son, Direc­tor of Clin­i­cal Tri­als at Lumosity - Nikhil Sri­ra­man, IP Ana­lyst at SharpBrains Presentation @ The 2015 SharpBrains Virtual Summit http://sharpbrains.com/summit-2015/agenda

1. Innovative partnerships to improve
health and life at scale

2. Innovative partnerships to improve
health and life at scale
Chaired by: Dr. Richard Varn,
Distinguished Presidential Appointee
at Educational Testing Services (ETS)
Tommy Sagroun,
CEO of CogniFit
Peter Freer,
Inventor and CEO
of Freer Logic
Glenn Morrison,
Director of Clinical Trials
at Lumosity
Nikhil Sriraman,
IP Analyst at SharpBrains

3. Tommy Sagroun, CEO
Innovative partnerships to
improve health and life at
scale

4. About the company
Founded in 1999 by neuroscientists
Computerized cognitive assessments and brain training software
Improve quality of life through brain fitness
15+ years of scientific validation: independent institutions and
peer-reviewed publications
B2B partnerships with large companies (industry: pharmacy,
education, driving, health and wellness) + B2C

5. What is MS?
Multiple sclerosis (MS): incurable disease of the CNS that
disrupts the flow of information within the brain and between
the brain and body
Symptoms:
 Physical: loss of muscle control, vision, balance, and sensation
 Hidden: fatigue, cognitive impairment, and socio-
psychological problems
Treatment: decrease the frequency of relapses and delay
disease progression

6. Bayer long-term commitment in MS
Bayer HealthCare Pharmaceuticals: first company to offer an
effective and innovative treatment for MS
Bayer optimizes existing therapies and offers physicians and
patients a complete help network, including a 360° support
approach:
 Effective MS therapy
 Innovative application system
 Direct MS-nurse support
 Informative and practical materials
How to help MS patients improve their cognition?

7. Peer-reviewed publications
Examples of peer-reviewed publications showing that CogniFit
programs help improve cognitive function:
 In MS patients
 In older adults
 In people with intellectual and developmental disabilities (IDD)
 And reduce depression levels in patients with unipolar and
bipolar disorder
 And improve sleep quality in older adults with insomnia
 And increase mobility in sedentary seniors
 And boost dyslexic students’ reading skills

8. Bayer and CogniFit collaboration
Bayer’s conundrum: how to improve cognition in MS patients?
CogniFit brain training is clinically proven to improve cognitive
skills in people with MS
CogniFit + Bayer = better care for MS patients by combining drugs
and brain training software

9. How does the CogniFit program work?
Peer reviewed publications – Proves scientific validity
Baseline assessment – Captures your cognitive profile
Personalized training – Builds your optimal training regimen
Real-time difficulty level adjustment – Keeps you challenged
Variety of games – Keeps you engaged
Diverse cognitive skills – Gets you a comprehensive workout
Constant training – Maintains your benefits

10. The partnership
Initial collaboration with Bayer global
Local Bayer entities review regulations and marketing strategies for
their market
CogniFit is available in 16 languages
First product’s rollout in Bayer’s parent company country
Bayer teams work locally with doctors, nurses and health care
providers

11. Key lessons
Largest global companies recognize brain fitness
CogniFit’s scientific credibility increases
Stronger patient involvement in fighting the disease
Customized brain fitness for specific targets
Other partnerships with companies from different industries such
as health and wellness and education
Dedicated online platforms for healthcare professionals, schools,
and researchers

12. Thank you
t.sagroun@cognifit.com
Tommy Sagroun, CEO

13. Innovative partnerships using neurotechnology
Putting the puzzle together Peter Freer, Freer Logic, LLC

14. Creation
 What constitutes a disruptive
neurotechnology?

15. Networking
How do I meet the right person in the
right company?

16. Research
 Review the company that you’re meeting with
noting their interests
 Review the person you are meeting with to know
what he/she is interested in

17. Development
• NASA
• Military
• NASCAR
• Nuclear Power
• Olympic teams

18. What to expect
 No overnight successes
 Slow moving companies with due
diligence processes
 Open the kimono
 Have an NDA
 Do you have a patent?

19. Create Buzz
 Create news about your product or service

20. Summary
 Perhaps the most critical factor once you’ve
had initial contact is follow-up
 No overnight successes
 Innovation drives your ability to get people
to use your tech
 Innovation is driven by needs

21. Privileged & Confidential
Lumos Labs, Inc.
Lumos Labs
SharpBrains Summit
18 November 2015
Glenn Morrison, PhD

22. LUMOS LABS, INC.
The Human Cognition Project
The HCP advances the science of cognitive enhancement through a
global, collaborative research network.

23. LUMOS LABS, INC.
Our Mission
• Create and validate training tools that aim to improve cognitive
abilities
• Create and validate assessment tools to measure cognitive
performance
• Advance the pace of cognitive science research
• Expand the understanding of the human brain

24. LUMOS LABS, INC.

25. LUMOS LABS, INC.
• Brain Health Registry (BHR) is a UCSF-based nonprofit website
designed to create a registry of individuals for recruitment into
clinical trials and investigator initiated research
• BHR currently has >35,000 members
• self report questionnaires
• neuropsychological tests
• informants/study partners information
• genetics (from spit kits or blood samples)
• devices
• Lumos Labs currently supports BHR by:
• Providing the NeuroCognitive Performance Test (NCPT) as one of
the online neuropsychological tests.
• Helping to recruit to the BHR by conducting targeted outreach to
Lumosity users

26. LUMOS LABS, INC.
Alzheimer’s Disease – A Case Study
• One major focus for the BHR is Alzheimer’s disease (AD)
• AD clinical trials face numerous challenges
• Slow recruitment
• High screen fail rate
• Partnering with BHR, Lumos has the opportunity to impact the way
in which AD research is conducted
In screening
- 25% at
memory test
- 25% with no
amyloid
- 25% for
other reasons
Enrolled
Screen 4000 to enroll 1000

27. LUMOS LABS, INC.
Alzheimer’s Disease – A Case Study
• Lumos Labs has over 70 million users, which provides a large
audience to invite to participate in research
• Participants who join the BHR take Lumos’ NCPT
• Goal to pre-identify those most likely to qualify for trial enrollment
At home
computerized
memory testing
- 10% at
memory
test
- 25% with
no amyloid
- 25% for
other
reasons
Enrolled
In screening
Identify those most
likely to ‘pass’
memory test
Screen 2500 to enroll 1000

28. LUMOS LABS, INC.
BHR and Lumos – A Mutually
Beneficial Partnership
• Partnership benefits goals of both BHR and Lumos
• BHR gains access to a potentially interested audience to help build
the registry
• Lumos contributes the NCPT to the BHR in an effort to advance
research
• Lumos gains access to data to help further validate the NCPT
• Other research opportunities emerge to advance goals of both
parties

29. LUMOS LABS, INC.
Examples of Other HCP Partnerships
• Partnership between Lumos, Anthrotronix,
Geoffrey Beene Foundation, BrightFocus,
US Against Alzheimer’s, and 21st Century
Braintrust
• Goal was to understand the impact of
providing care for dementia patients
• Partnership between Lumos, Alzheimer’s
Prevention Initiative, and University of
Antioquia
• Lumos partnering to build awareness of
familial AD registry in Colombia by reaching
out to users
• Collecting cognitive data on families with
genetic predisposition for early onset AD

30. LUMOS LABS, INC.
Supporting Academia and Advancing
Neuroscience Research
• More than 100 academic collaborators
• 60 academic institutions
• Global outreach

31. LUMOS LABS, INC.
How to Get Involved
• We review proposals quarterly, and our next scheduled review will take
place in December
• We evaluate research studies by considering the following criteria:
1. adequate sample size
2. total training time of 20 hours or greater
3. sufficient randomization and active controls
4. relevant outcomes measures or assessments
5. processes and controls to ensure study integrity
6. suitability of investigator(s) and institution
Visit: http://www.lumosity.com/hcp/research/about

32. Pervasive Neurotech Partnerships
and Innovations
Nikhil Sriraman
SharpBrains Analyst

33. Why we identified
non-invasive neurotech patents

34. How we identified
non-invasive neurotech patents
4K+ US non-invasive
neurotech patents
10K+ GLOBAL pubs
yielded w/ similar
process

35. Five key trends and insights
1. Exponential growth since 2010
1. Large companies with strong portfolios
1. Evolution from invasive to pervasive
1. Multi-sensor, multi-variable data analysis
2. Aggressive “build” AND “buy”

36. 1. Exponential growth in neurotech

37. Portfolio strength assessed via SharpBrains Index
2. Large companies emerge as
leading IP holders

38. 3. Exemplary portfolio –
from invasive to pervasive

39. 4. Exemplary portfolio –
multi-sensor, multi-variable analysis

40. 5. Aggressive “build” and “buy”

42. Questions?

43. Thank you for another fun day
Sponsors

44. Next Steps:
1) Expo Day tomorrow!
2) To discuss: Summit’s LinkedIn Group
3) Recordings and Handouts

45. To learn more, visit sharpbrains.com